Phytotherapy of Vulvovaginal Candidiasis: A Narrative Review.
Natalia PichetaJulia PiekarzOliwia BurdanMałgorzata SatoraRafał TarkowskiKrzysztof KułakPublished in: International journal of molecular sciences (2024)
Vulvovaginal candidiasis (VVC) is a real gynecological problem among women of reproductive age from 15 to 49. A recent analysis showed that 75% of women will have an occurrence at least once per year, while 5% are observed to have recurrent vaginal mycosis-these patients may become unwell four or more times a year. This pathology is caused in 85-90% of cases by fungi of the Candida albicans species. It represents an intractable medical problem for female patients due to pain and pruritus. Due to the observation of an increasing number of strains resistant to standard preparations and an increase in the recurrence of this pathology when using local or oral preferential therapy, such as fluconazole, an analysis was launched to develop alternative methods of treating VVC using herbs such as dill, turmeric, and berberine. An in-depth analysis of databases that include scientific articles from recent years made it possible to draw satisfactory conclusions supporting the validity of herbal therapy for the pathology in question. Although phytotherapy has not yet been approved by the Food and Drug Administration, it appears to be a promising therapeutic solution for strains that are resistant to existing treatments. There is research currently undergoing aimed at comparing classical pharmacotherapy and herbal therapy in the treatment of vaginal candidiasis for the purpose of increasing medical competence and knowledge for the care of the health and long-term comfort of gynecological patients.
Keyphrases
- candida albicans
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- escherichia coli
- prognostic factors
- palliative care
- peritoneal dialysis
- public health
- chronic pain
- type diabetes
- polycystic ovary syndrome
- pregnant women
- stem cells
- mesenchymal stem cells
- cystic fibrosis
- mental health
- drug administration
- insulin resistance
- adipose tissue
- cell therapy
- metabolic syndrome
- pregnancy outcomes
- affordable care act
- bone marrow
- combination therapy
- pain management
- artificial intelligence
- replacement therapy
- optical coherence tomography
- postoperative pain